Skip to main content

Table 5 Odds ratios for having the metabolic syndrome in patients receiving methotrexate compared with those not on methotrexate

From: Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study

  Odds ratio 95% confidence interval P value
Crude 0.483 0.32 to 0.73 0.001
Model a 0.505 0.33 to 0.77 0.001
Model b 0.525 0.34 to 0.80 0.003
Model c 0.517 0.33 to 0.80 0.004
  1. Crude = unadjusted model
  2. Model a = adjusted for age and sex
  3. Model b = adjusted for age, sex, disease duration, erythrocyte sedimentation rate and health assessment questionnaire score
  4. Model c = adjusted for age, sex, disease duration, erythrocyte sedimentation rate, health assessment questionnaire score, sulphasalazine, hydroxyxhloroquine, leflunomide, anti-tumour necrosis factor therapy, glucocorticoid use and NSAID use.